Willows Referral Services, Shirley, Solihull, UK.
Veterinary Dermatology Riga, SIA Olivry Consulting, Riga, Latvia.
Vet Dermatol. 2023 Feb;34(1):53-58. doi: 10.1111/vde.13128. Epub 2022 Oct 13.
The treatment of canine chronic cutaneous lupus erythematosus (CCLE) variants generally requires immunosuppression, which often results in potentially severe adverse effects. Janus kinase inhibitors, like oclacitinib, might be a valuable treatment option due to their rapid inhibition of the action of interferons known to be relevant in the pathogenesis of CCLE.
To report the efficacy and safety of oral oclacitinib for the treatment of canine CCLE variants.
Seven dogs were diagnosed with CCLE based on clinical signs and compatible histopathological findings.
Oclacitinib was administered at the induction dosage of 0.45 mg/kg twice daily to 1.8 mg/kg once daily. The response to treatment was graded as 'good' when there was ≥50% lesion reduction, or as 'complete remission' if all active lesions had resolved. Complete blood counts were performed at variable intervals.
A complete remission of all lesions was obtained in the dog with exfoliative cutaneous lupus erythematosus, both dogs with mucocutaneous lupus erythematosus and three of four dogs with facial discoid lupus erythematosus (FDLE); a good response was seen in the remaining dog with FDLE. The first visible improvement of signs was seen within 2-to-3 weeks, while the time to complete remission was around 2 months. Clinical adverse effects were not seen, and haematological parameters remained within the reference range.
Oclacitinib may be considered an effective treatment option for different variants of canine CCLE.
犬慢性皮肤红斑狼疮（CCLE）各变异型的治疗通常需要免疫抑制，这往往会导致潜在的严重不良反应。Janus 激酶抑制剂，如oclacitinib，由于其能够快速抑制干扰素的作用，而干扰素被认为与 CCLE 的发病机制有关，因此可能是一种有价值的治疗选择。
报告口服 oclacitinib 治疗犬 CCLE 各变异型的疗效和安全性。
根据临床症状和相符的组织病理学发现，7 只犬被诊断为 CCLE。
oclacitinib 的起始剂量为 0.45 mg/kg，每日两次，逐渐增加至 1.8 mg/kg，每日一次。治疗反应的分级为：病变减少≥50%为“良好”，所有活动性病变均消退为“完全缓解”。在不同时间间隔进行全血细胞计数。
在 1 只剥脱性皮肤红斑狼疮犬、2 只黏膜皮肤红斑狼疮犬和 4 只盘状红斑狼疮犬中的 3 只，所有病变完全缓解；4 只盘状红斑狼疮犬中的 1 只病变得到“良好”缓解。在 2-3 周内即可观察到症状的首次明显改善，而达到完全缓解的时间约为 2 个月。未观察到临床不良反应，且血液学参数仍在参考范围内。
oclacitinib 可被视为犬 CCLE 各变异型的有效治疗选择。
